-
1
-
-
84861527388
-
The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups
-
10.1038/nature10983
-
Curtis C, Shah SP, Chin SF et al (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. doi: 10.1038/nature10983
-
(2012)
Nature
-
-
Curtis, C.1
Shah, S.P.2
Chin, S.F.3
-
2
-
-
79960980007
-
Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011
-
10.1093/annonc/mdr304 21709140 10.1093/annonc/mdr304 1:STN:280: DC%2BC3Mjhs1ygug%3D%3D
-
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ, Panel M (2011) Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22:1736-1747. doi: 10.1093/annonc/mdr304
-
(2011)
Ann Oncol
, vol.22
, pp. 1736-1747
-
-
Goldhirsch, A.1
Wood, W.C.2
Coates, A.S.3
Gelber, R.D.4
Thurlimann, B.5
Senn, H.J.6
Panel, M.7
-
3
-
-
77950512587
-
Breast cancer subtypes and the risk of local and regional relapse
-
10.1200/JCO.2009.24.9284 20194857 10.1200/JCO.2009.24.9284
-
Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H (2010) Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 28:1684-1691. doi: 10.1200/JCO.2009.24.9284
-
(2010)
J Clin Oncol
, vol.28
, pp. 1684-1691
-
-
Voduc, K.D.1
Cheang, M.C.2
Tyldesley, S.3
Gelmon, K.4
Nielsen, T.O.5
Kennecke, H.6
-
4
-
-
35248895346
-
HER2 and response to paclitaxel in node-positive breast cancer
-
Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Cancer, Leukemia Group BI 10.1056/NEJMoa071167 10.1056/NEJMoa071167
-
Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA, Cancer, Leukemia Group BI (2007) HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med 357:1496-1506. doi: 10.1056/NEJMoa071167
-
(2007)
N Engl J Med
, vol.357
, pp. 1496-1506
-
-
-
5
-
-
40149100006
-
Expression of ER, PgR, HER1, HER2, and response: A study of preoperative chemotherapy
-
10.1093/annonc/mdm509 17986623 10.1093/annonc/mdm509 1:STN:280: DC%2BD1c7ksVWlsA%3D%3D
-
Colleoni M, Viale G, Zahrieh D, Bottiglieri L, Gelber RD, Veronesi P, Balduzzi A, Torrisi R, Luini A, Intra M, Dellapasqua S, Cardillo A, Ghisini R, Peruzzotti G, Goldhirsch A (2008) Expression of ER, PgR, HER1, HER2, and response: a study of preoperative chemotherapy. Ann Oncol 19:465-472. doi: 10.1093/annonc/mdm509
-
(2008)
Ann Oncol
, vol.19
, pp. 465-472
-
-
Colleoni, M.1
Viale, G.2
Zahrieh, D.3
Bottiglieri, L.4
Gelber, R.D.5
Veronesi, P.6
Balduzzi, A.7
Torrisi, R.8
Luini, A.9
Intra, M.10
Dellapasqua, S.11
Cardillo, A.12
Ghisini, R.13
Peruzzotti, G.14
Goldhirsch, A.15
-
6
-
-
26844503270
-
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T 10.1056/NEJMoa052306 10.1056/NEJMoa052306
-
Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, Smith I, Gianni L, Baselga J, Bell R, Jackisch C, Cameron D, Dowsett M, Barrios CH, Steger G, Huang CS, Andersson M, Inbar M, Lichinitser M, Lang I, Nitz U, Iwata H, Thomssen C, Lohrisch C, Suter TM, Ruschoff J, Suto T, Greatorex V, Ward C, Straehle C, McFadden E, Dolci MS, Gelber RD, Herceptin Adjuvant Trial Study T (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353:1659-1672. doi: 10.1056/NEJMoa052306
-
(2005)
N Engl J Med
, vol.353
, pp. 1659-1672
-
-
-
7
-
-
26844536978
-
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
-
10.1056/NEJMoa052122 16236738 10.1056/NEJMoa052122 1:CAS:528: DC%2BD2MXhtFansr3F
-
Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein PM, Ingle JN, Wolmark N (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353:1673-1684. doi: 10.1056/NEJMoa052122
-
(2005)
N Engl J Med
, vol.353
, pp. 1673-1684
-
-
Romond, E.H.1
Perez, E.A.2
Bryant, J.3
Suman, V.J.4
Geyer, Jr.C.E.5
Davidson, N.E.6
Tan-Chiu, E.7
Martino, S.8
Paik, S.9
Kaufman, P.A.10
Swain, S.M.11
Pisansky, T.M.12
Fehrenbacher, L.13
Kutteh, L.A.14
Vogel, V.G.15
Visscher, D.W.16
Yothers, G.17
Jenkins, R.B.18
Brown, A.M.19
Dakhil, S.R.20
Mamounas, E.P.21
Lingle, W.L.22
Klein, P.M.23
Ingle, J.N.24
Wolmark, N.25
more..
-
8
-
-
33646439130
-
Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): A review of the literature
-
10.1200/JCO.2005.02.8035 16648513 10.1200/JCO.2005.02.8035
-
Hanrahan EO, Valero V, Gonzalez-Angulo AM, Hortobagyi GN (2006) Prognosis and management of patients with node-negative invasive breast carcinoma that is 1 cm or smaller in size (stage 1; T1a, bN0M0): a review of the literature. J Clin Oncol 24:2113-2122. doi: 10.1200/JCO.2005.02.8035
-
(2006)
J Clin Oncol
, vol.24
, pp. 2113-2122
-
-
Hanrahan, E.O.1
Valero, V.2
Gonzalez-Angulo, A.M.3
Hortobagyi, G.N.4
-
9
-
-
0035900920
-
Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes
-
11208880 10.1093/jnci/93.2.112 1:STN:280:DC%2BD3M7nvF2ltg%3D%3D
-
Fisher B, Dignam J, Tan-Chiu E, Anderson S, Fisher ER, Wittliff JL, Wolmark N (2001) Prognosis and treatment of patients with breast tumors of one centimeter or less and negative axillary lymph nodes. J Natl Cancer Inst 93:112-120
-
(2001)
J Natl Cancer Inst
, vol.93
, pp. 112-120
-
-
Fisher, B.1
Dignam, J.2
Tan-Chiu, E.3
Anderson, S.4
Fisher, E.R.5
Wittliff, J.L.6
Wolmark, N.7
-
10
-
-
79958267860
-
Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes
-
10.1007/s10549-011-1465-7 21452022 10.1007/s10549-011-1465-7 1:STN:280:DC%2BC3MrjsFWmtg%3D%3D
-
Cancello G, Maisonneuve P, Rotmensz N, Viale G, Mastropasqua MG, Pruneri G, Montagna E, Dellapasqua S, Iorfida M, Cardillo A, Veronesi P, Luini A, Intra M, Gentilini O, Scarano E, Goldhirsch A, Colleoni M (2011) Prognosis in women with small (T1mic, T1a, T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat 127:713-720. doi: 10.1007/s10549-011-1465-7
-
(2011)
Breast Cancer Res Treat
, vol.127
, pp. 713-720
-
-
Cancello, G.1
Maisonneuve, P.2
Rotmensz, N.3
Viale, G.4
Mastropasqua, M.G.5
Pruneri, G.6
Montagna, E.7
Dellapasqua, S.8
Iorfida, M.9
Cardillo, A.10
Veronesi, P.11
Luini, A.12
Intra, M.13
Gentilini, O.14
Scarano, E.15
Goldhirsch, A.16
Colleoni, M.17
-
11
-
-
73349119689
-
High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller
-
10.1200/JCO.2009.23.2025 19884543 10.1200/JCO.2009.23.2025
-
Gonzalez-Angulo AM, Litton JK, Broglio KR, Meric-Bernstam F, Rakkhit R, Cardoso F, Peintinger F, Hanrahan EO, Sahin A, Guray M, Larsimont D, Feoli F, Stranzl H, Buchholz TA, Valero V, Theriault R, Piccart-Gebhart M, Ravdin PM, Berry DA, Hortobagyi GN (2009) High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller. J Clin Oncol 27:5700-5706. doi: 10.1200/JCO.2009.23. 2025
-
(2009)
J Clin Oncol
, vol.27
, pp. 5700-5706
-
-
Gonzalez-Angulo, A.M.1
Litton, J.K.2
Broglio, K.R.3
Meric-Bernstam, F.4
Rakkhit, R.5
Cardoso, F.6
Peintinger, F.7
Hanrahan, E.O.8
Sahin, A.9
Guray, M.10
Larsimont, D.11
Feoli, F.12
Stranzl, H.13
Buchholz, T.A.14
Valero, V.15
Theriault, R.16
Piccart-Gebhart, M.17
Ravdin, P.M.18
Berry, D.A.19
Hortobagyi, G.N.20
more..
-
12
-
-
84867330656
-
Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy
-
10.1002/cncr.27480 22392492 10.1002/cncr.27480
-
Ho AY, Gupta G, King TA, Perez CA, Patil SM, Rogers KH, Wen YH, Brogi E, Morrow M, Hudis CA, Traina T, McCormick B, Powell SN, Robson ME (2012) Favorable prognosis in patients with T1a/T1bN0 triple-negative breast cancers treated with multimodality therapy. Cancer 118:4944-4952. doi: 10.1002/cncr.27480
-
(2012)
Cancer
, vol.118
, pp. 4944-4952
-
-
Ho, A.Y.1
Gupta, G.2
King, T.A.3
Perez, C.A.4
Patil, S.M.5
Rogers, K.H.6
Wen, Y.H.7
Brogi, E.8
Morrow, M.9
Hudis, C.A.10
Traina, T.11
McCormick, B.12
Powell, S.N.13
Robson, M.E.14
-
13
-
-
77957924786
-
Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less
-
10.1186/1471-2407-10-557 20946688 10.1186/1471-2407-10-557
-
Kwon JH, Kim YJ, Lee KW, Oh DY, Park SY, Kim JH, Chie EK, Kim SW, Im SA, Kim IA, Kim TY, Park IA, Noh DY, Bang YJ, Ha SW (2010) Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less. BMC Cancer 10:557. doi: 10.1186/1471-2407-10-557
-
(2010)
BMC Cancer
, vol.10
, pp. 557
-
-
Kwon, J.H.1
Kim, Y.J.2
Lee, K.W.3
Oh, D.Y.4
Park, S.Y.5
Kim, J.H.6
Chie, E.K.7
Kim, S.W.8
Im, S.A.9
Kim, I.A.10
Kim, T.Y.11
Park, I.A.12
Noh, D.Y.13
Bang, Y.J.14
Ha, S.W.15
-
14
-
-
78049427459
-
Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas
-
10.1200/JCO.2010.29.7952 20660834 10.1200/JCO.2010.29.7952
-
Rodrigues MJ, Wassermann J, Albiges L, Brain E, Delaloge S, Stevens D, Guinebretiere JM, Mathieu MC, Kirova Y, Guillot E, Vincent-Salomon A, Cottu PH (2010) Trastuzumab treatment in t1ab, node-negative, human epidermal growth factor receptor 2-overexpressing breast carcinomas. J Clin Oncol 28:e541-e542. doi: 10.1200/JCO.2010.29.7952
-
(2010)
J Clin Oncol
, vol.28
-
-
Rodrigues, M.J.1
Wassermann, J.2
Albiges, L.3
Brain, E.4
Delaloge, S.5
Stevens, D.6
Guinebretiere, J.M.7
Mathieu, M.C.8
Kirova, Y.9
Guillot, E.10
Vincent-Salomon, A.11
Cottu, P.H.12
-
16
-
-
84874662033
-
Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer
-
abstract 1034
-
Migdady Y, Sikov WM, Sakr BJ, Olszewski AJ (2012) Impact of adjuvant chemotherapy on recurrence-free survival in patients with pT1a/b hormone-negative and HER2-positive breast cancer. J Clin Oncol 30, No 15-suppl: abstract 1034
-
(2012)
J Clin Oncol
, vol.30
, Issue.15 SUPPL.
-
-
Migdady, Y.1
Sikov, W.M.2
Sakr, B.J.3
Olszewski, A.J.4
-
17
-
-
77954526150
-
American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
-
10.1200/JCO.2009.25.6529 20404251 10.1200/JCO.2009.25.6529
-
Hammond ME, Hayes DF, Dowsett M et al (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784-2795. doi: 10.1200/JCO.2009.25.6529
-
(2010)
J Clin Oncol
, vol.28
, pp. 2784-2795
-
-
Hammond, M.E.1
Hayes, D.F.2
Dowsett, M.3
-
18
-
-
33847147313
-
American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer
-
10.1200/JCO.2006.09.2775 17159189 10.1200/JCO.2006.09.2775 1:CAS:528:DC%2BD2sXht1ejs7Y%3D
-
Wolff AC, Hammond ME, Schwartz JN et al (2007) American society of clinical oncology/college of American pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118-145. doi: 10.1200/JCO.2006.09.2775
-
(2007)
J Clin Oncol
, vol.25
, pp. 118-145
-
-
Wolff, A.C.1
Hammond, M.E.2
Schwartz, J.N.3
-
19
-
-
34249942379
-
Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: The STEEP system
-
10.1200/JCO.2006.10.3523 17513820 10.1200/JCO.2006.10.3523
-
Hudis CA, Barlow WE, Costantino JP, Gray RJ, Pritchard KI, Chapman JA, Sparano JA, Hunsberger S, Enos RA, Gelber RD, Zujewski JA (2007) Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 25:2127-2132. doi: 10.1200/JCO.2006.10. 3523
-
(2007)
J Clin Oncol
, vol.25
, pp. 2127-2132
-
-
Hudis, C.A.1
Barlow, W.E.2
Costantino, J.P.3
Gray, R.J.4
Pritchard, K.I.5
Chapman, J.A.6
Sparano, J.A.7
Hunsberger, S.8
Enos, R.A.9
Gelber, R.D.10
Zujewski, J.A.11
-
20
-
-
79958704133
-
An introduction to propensity score methods for reducing the effects of confounding in observational studies
-
10.1080/00273171.2011.568786 10.1080/00273171.2011.568786
-
Austin PC (2011) An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar Behav Res 46:399-424. doi: 10.1080/00273171.2011.568786
-
(2011)
Multivar Behav Res
, vol.46
, pp. 399-424
-
-
Austin, P.C.1
-
21
-
-
79960909793
-
Are propensity scores really superior to standard multivariable analysis?
-
10.1016/j.cct.2011.05.006 21616172 10.1016/j.cct.2011.05.006
-
Biondi-Zoccai G, Romagnoli E, Agostoni P, Capodanno D, Castagno D, D'Ascenzo F, Sangiorgi G, Modena MG (2011) Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials 32:731-740. doi: 10.1016/j.cct.2011.05.006
-
(2011)
Contemp Clin Trials
, vol.32
, pp. 731-740
-
-
Biondi-Zoccai, G.1
Romagnoli, E.2
Agostoni, P.3
Capodanno, D.4
Castagno, D.5
D'Ascenzo, F.6
Sangiorgi, G.7
Modena, M.G.8
-
22
-
-
0041626110
-
Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders
-
12882951 10.1093/aje/kwg115
-
Cepeda MS, Boston R, Farrar JT, Strom BL (2003) Comparison of logistic regression versus propensity score when the number of events is low and there are multiple confounders. Am J Epidemiol 158:280-287
-
(2003)
Am J Epidemiol
, vol.158
, pp. 280-287
-
-
Cepeda, M.S.1
Boston, R.2
Farrar, J.T.3
Strom, B.L.4
-
23
-
-
0033839024
-
Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men
-
10955409 10.1097/00001648-200009000-00012 1:STN:280: DC%2BD3M%2FntlSnsA%3D%3D
-
Hernan MA, Brumback B, Robins JM (2000) Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology 11:561-570
-
(2000)
Epidemiology
, vol.11
, pp. 561-570
-
-
Hernan, M.A.1
Brumback, B.2
Robins, J.M.3
-
24
-
-
51749124303
-
Constructing inverse probability weights for marginal structural models
-
10.1093/aje/kwn164 18682488 10.1093/aje/kwn164
-
Cole SR, Hernan MA (2008) Constructing inverse probability weights for marginal structural models. Am J Epidemiol 168:656-664. doi: 10.1093/aje/kwn164
-
(2008)
Am J Epidemiol
, vol.168
, pp. 656-664
-
-
Cole, S.R.1
Hernan, M.A.2
-
25
-
-
77957806232
-
Matching methods for causal inference: A review and a look forward
-
10.1214/09-STS313 20871802 10.1214/09-STS313
-
Stuart EA (2010) Matching methods for causal inference: a review and a look forward. Stat Sci 25:1-21. doi: 10.1214/09-STS313
-
(2010)
Stat Sci
, vol.25
, pp. 1-21
-
-
Stuart, E.A.1
-
26
-
-
70449365700
-
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
-
10.1002/sim.3697 19757444 10.1002/sim.3697
-
Austin PC (2009) Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 28:3083-3107. doi: 10.1002/sim.3697
-
(2009)
Stat Med
, vol.28
, pp. 3083-3107
-
-
Austin, P.C.1
-
27
-
-
77957301897
-
Treatment effects in the presence of unmeasured confounding: Dealing with observations in the tails of the propensity score distribution - A simulation study
-
10.1093/aje/kwq198 20716704 10.1093/aje/kwq198
-
Sturmer T, Rothman KJ, Avorn J, Glynn RJ (2010) Treatment effects in the presence of unmeasured confounding: dealing with observations in the tails of the propensity score distribution-a simulation study. Am J Epidemiol 172:843-854. doi: 10.1093/aje/kwq198
-
(2010)
Am J Epidemiol
, vol.172
, pp. 843-854
-
-
Sturmer, T.1
Rothman, K.J.2
Avorn, J.3
Glynn, R.J.4
-
28
-
-
50549102861
-
Choice and interpretation of statistical tests used when competing risks are present
-
10.1200/JCO.2007.12.9866 18711194 10.1200/JCO.2007.12.9866
-
Dignam JJ, Kocherginsky MN (2008) Choice and interpretation of statistical tests used when competing risks are present. J Clin Oncol 26:4027-4034. doi: 10.1200/JCO.2007.12.9866
-
(2008)
J Clin Oncol
, vol.26
, pp. 4027-4034
-
-
Dignam, J.J.1
Kocherginsky, M.N.2
-
29
-
-
78049445066
-
Pitfalls of using composite primary end points in the presence of competing risks
-
10.1200/JCO.2010.30.2802 20713860 10.1200/JCO.2010.30.2802
-
Mell LK, Jeong JH (2010) Pitfalls of using composite primary end points in the presence of competing risks. J Clin Oncol 28:4297-4299. doi: 10.1200/JCO.2010.30.2802
-
(2010)
J Clin Oncol
, vol.28
, pp. 4297-4299
-
-
Mell, L.K.1
Jeong, J.H.2
-
30
-
-
1542532754
-
A proportional hazards model for the subdistribution of a competing risk
-
10.1080/01621459.1999.10474144
-
Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496-509
-
(1999)
J Am Stat Assoc
, vol.94
, pp. 496-509
-
-
Fine, J.P.1
Gray, R.J.2
-
31
-
-
80155164070
-
Coping with uncertainty: T1a, bN0M0 HER2-positive breast cancer, do we have a treatment threshold?
-
10.1093/annonc/mdq786 21406473 10.1093/annonc/mdq786 1:STN:280: DC%2BC3MbjsFSgsw%3D%3D
-
Kelly CM, Pritchard KI, Trudeau M, Andreopoulou E, Hess K, Pusztai L (2011) Coping with uncertainty: T1a, bN0M0 HER2-positive breast cancer, do we have a treatment threshold? Ann Oncol 22:2387-2393. doi: 10.1093/annonc/mdq786
-
(2011)
Ann Oncol
, vol.22
, pp. 2387-2393
-
-
Kelly, C.M.1
Pritchard, K.I.2
Trudeau, M.3
Andreopoulou, E.4
Hess, K.5
Pusztai, L.6
-
32
-
-
73349142700
-
Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer
-
10.1200/JCO.2009.22.0962 19884553 10.1200/JCO.2009.22.0962
-
Curigliano G, Viale G, Bagnardi V, Fumagalli L, Locatelli M, Rotmensz N, Ghisini R, Colleoni M, Munzone E, Veronesi P, Zurrida S, Nole F, Goldhirsch A (2009) Clinical relevance of HER2 overexpression/amplification in patients with small tumor size and node-negative breast cancer. J Clin Oncol 27:5693-5699. doi: 10.1200/JCO.2009.22.0962
-
(2009)
J Clin Oncol
, vol.27
, pp. 5693-5699
-
-
Curigliano, G.1
Viale, G.2
Bagnardi, V.3
Fumagalli, L.4
Locatelli, M.5
Rotmensz, N.6
Ghisini, R.7
Colleoni, M.8
Munzone, E.9
Veronesi, P.10
Zurrida, S.11
Nole, F.12
Goldhirsch, A.13
-
33
-
-
78650295428
-
Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller
-
10.1016/j.ejso.2010.10.003 21093206 10.1016/j.ejso.2010.10.003 1:STN:280:DC%2BC3M%2FjsFCmtg%3D%3D
-
Lai HW, Kuo SJ, Chen LS, Chi CW, Chen ST, Chang TW, Chen DR (2011) Prognostic significance of triple negative breast cancer at tumor size 1 cm and smaller. Eur J Surg Oncol 37:18-24. doi: 10.1016/j.ejso.2010.10.003
-
(2011)
Eur J Surg Oncol
, vol.37
, pp. 18-24
-
-
Lai, H.W.1
Kuo, S.J.2
Chen, L.S.3
Chi, C.W.4
Chen, S.T.5
Chang, T.W.6
Chen, D.R.7
-
34
-
-
77958571366
-
Prognosis and outcome of small (<=1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status
-
10.1634/theoncologist.2010-0036 20930097 10.1634/theoncologist.2010-0036 1:CAS:528:DC%2BC3cXhsFyqsrbI
-
Amar S, McCullough AE, Tan W, Geiger XJ, Boughey JC, McNeil RB, Coppola KE, McLaughlin SA, Palmieri FM, Perez EA (2010) Prognosis and outcome of small (≤1 cm), node-negative breast cancer on the basis of hormonal and HER-2 status. Oncologist 15:1043-1049. doi: 10.1634/theoncologist.2010-0036
-
(2010)
Oncologist
, vol.15
, pp. 1043-1049
-
-
Amar, S.1
McCullough, A.E.2
Tan, W.3
Geiger, X.J.4
Boughey, J.C.5
McNeil, R.B.6
Coppola, K.E.7
McLaughlin, S.A.8
Palmieri, F.M.9
Perez, E.A.10
-
35
-
-
70449645182
-
T1N0 triple negative breast cancer: Risk of recurrence and adjuvant chemotherapy
-
10.1111/j.1524-4741.2009.00789.x 19671105 10.1111/j.1524-4741.2009.00789. x
-
Kaplan HG, Malmgren JA, Atwood M (2009) T1N0 triple negative breast cancer: risk of recurrence and adjuvant chemotherapy. Breast J 15:454-460. doi: 10.1111/j.1524-4741.2009.00789.x
-
(2009)
Breast J
, vol.15
, pp. 454-460
-
-
Kaplan, H.G.1
Malmgren, J.A.2
Atwood, M.3
-
36
-
-
82955233117
-
Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer
-
10.1002/cncr.26171 21681735 10.1002/cncr.26171 1:CAS:528: DC%2BC3MXhsFGktrrN
-
McArthur HL, Mahoney KM, Morris PG, Patil S, Jacks LM, Howard J, Norton L, Hudis CA (2011) Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer. Cancer 117:5461-5468. doi: 10.1002/cncr.26171
-
(2011)
Cancer
, vol.117
, pp. 5461-5468
-
-
McArthur, H.L.1
Mahoney, K.M.2
Morris, P.G.3
Patil, S.4
Jacks, L.M.5
Howard, J.6
Norton, L.7
Hudis, C.A.8
-
37
-
-
84874657287
-
Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: A multicenter retrospective series
-
10.1093/annonc/mds536
-
Rodrigues MJ, Peron J, Frenel JS, Vano YA, Wassermann J, Debled M, Picaud F, Albiges L, Vincent-Salomon A, Cottu PH (2012) Benefit of adjuvant trastuzumab-based chemotherapy in T1ab node-negative HER2-overexpressing breast carcinomas: a multicenter retrospective series. Ann Oncol. doi: 10.1093/annonc/mds536
-
(2012)
Ann Oncol
-
-
Rodrigues, M.J.1
Peron, J.2
Frenel, J.S.3
Vano, Y.A.4
Wassermann, J.5
Debled, M.6
Picaud, F.7
Albiges, L.8
Vincent-Salomon, A.9
Cottu, P.H.10
-
38
-
-
0037108675
-
National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less
-
12377957 10.1200/JCO.2002.11.101 1:CAS:528:DC%2BD38XnsFyqsLg%3D
-
Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N, National Surgical Adjuvant Breast and Bowel Project (2002) Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 20:4141-4149. doi: 10.1200/JCO.2002.11.101
-
(2002)
J Clin Oncol
, vol.20
, pp. 4141-4149
-
-
Fisher, B.1
Bryant, J.2
Dignam, J.J.3
Wickerham, D.L.4
Mamounas, E.P.5
Fisher, E.R.6
Margolese, R.G.7
Nesbitt, L.8
Paik, S.9
Pisansky, T.M.10
Wolmark, N.11
-
39
-
-
34548533485
-
Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer
-
10.1200/JCO.2006.10.4976 17664460 10.1200/JCO.2006.10.4976 1:CAS:528:DC%2BD2sXhtFanu7zI
-
Pinder MC, Duan Z, Goodwin JS, Hortobagyi GN, Giordano SH (2007) Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer. J Clin Oncol 25:3808-3815. doi: 10.1200/JCO.2006.10.4976
-
(2007)
J Clin Oncol
, vol.25
, pp. 3808-3815
-
-
Pinder, M.C.1
Duan, Z.2
Goodwin, J.S.3
Hortobagyi, G.N.4
Giordano, S.H.5
-
40
-
-
84855746053
-
Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype
-
10.1016/j.clbc.2011.05.002 21764391 10.1016/j.clbc.2011.05.002
-
Theriault RL, Litton JK, Mittendorf EA, Chen H, Meric-Bernstam F, Chavez-Macgregor M, Morrow PK, Woodward WA, Sahin A, Hortobagyi GN, Gonzalez-Angulo AM (2011) Age and survival estimates in patients who have node-negative T1ab breast cancer by breast cancer subtype. Clin Breast Cancer 11:325-331. doi: 10.1016/j.clbc.2011.05.002
-
(2011)
Clin Breast Cancer
, vol.11
, pp. 325-331
-
-
Theriault, R.L.1
Litton, J.K.2
Mittendorf, E.A.3
Chen, H.4
Meric-Bernstam, F.5
Chavez-Macgregor, M.6
Morrow, P.K.7
Woodward, W.A.8
Sahin, A.9
Hortobagyi, G.N.10
Gonzalez-Angulo, A.M.11
-
41
-
-
72449125237
-
Relationship between age at diagnosis and outcome of premenopausal breast cancer: Age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer
-
10.1007/s10549-009-0388-z 19350387 10.1007/s10549-009-0388-z
-
Han W, Kang SY (2010) Relationship between age at diagnosis and outcome of premenopausal breast cancer: age less than 35 years is a reasonable cut-off for defining young age-onset breast cancer. Breast Cancer Res Treat 119:193-200. doi: 10.1007/s10549-009-0388-z
-
(2010)
Breast Cancer Res Treat
, vol.119
, pp. 193-200
-
-
Han, W.1
Kang, S.Y.2
-
42
-
-
84857700943
-
Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling
-
10.1158/1078-0432.CCR-11-2599 22261811 10.1158/1078-0432.CCR-11-2599 1:CAS:528:DC%2BC38Xjt1Wltb4%3D
-
Azim HA Jr, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M, Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S (2012) Elucidating prognosis and biology of breast cancer arising in young women using gene expression profiling. Clin Cancer Res 18:1341-1351. doi: 10.1158/1078-0432.CCR-11-2599
-
(2012)
Clin Cancer Res
, vol.18
, pp. 1341-1351
-
-
Azim, Jr.H.A.1
Michiels, S.2
Bedard, P.L.3
Singhal, S.K.4
Criscitiello, C.5
Ignatiadis, M.6
Haibe-Kains, B.7
Piccart, M.J.8
Sotiriou, C.9
Loi, S.10
-
43
-
-
82155176361
-
T1abN0M0 HER2+ invasive breast cancer recurrence: Population-based cohort of 17,000+ consecutive breast cancers 2000-2006 at Kaiser Permanente Northern California (KPNC)
-
abstract 551
-
Fehrenbacher L, Shiraz P, Sattavat M, Capra A, Quesenberry C, Fulton R, Habel LA (2011) T1abN0M0 HER2+ invasive breast cancer recurrence: Population-based cohort of 17,000+ consecutive breast cancers 2000-2006 at Kaiser Permanente Northern California (KPNC). J Clin Oncol 29, No 15-suppl: abstract 551
-
(2011)
J Clin Oncol
, vol.29
, Issue.15 SUPPL.
-
-
Fehrenbacher, L.1
Shiraz, P.2
Sattavat, M.3
Capra, A.4
Quesenberry, C.5
Fulton, R.6
Habel, L.A.7
-
44
-
-
57749118336
-
Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer
-
10.1186/bcr2128 18681955 10.1186/bcr2128
-
Tamimi RM, Baer HJ, Marotti J, Galan M, Galaburda L, Fu Y, Deitz AC, Connolly JL, Schnitt SJ, Colditz GA, Collins LC (2008) Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer. Breast Cancer Res 10:R67. doi: 10.1186/bcr2128
-
(2008)
Breast Cancer Res
, vol.10
, pp. 67
-
-
Tamimi, R.M.1
Baer, H.J.2
Marotti, J.3
Galan, M.4
Galaburda, L.5
Fu, Y.6
Deitz, A.C.7
Connolly, J.L.8
Schnitt, S.J.9
Colditz, G.A.10
Collins, L.C.11
-
45
-
-
77951641554
-
Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome
-
10.1200/JCO.2009.22.8775 20231686 10.1200/JCO.2009.22.8775
-
Staaf J, Ringner M, Vallon-Christersson J, Jonsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Ferno M, Malmstrom PO, Johannsson OT, Loman N, Barkardottir RB, Borg A (2010) Identification of subtypes in human epidermal growth factor receptor 2-positive breast cancer reveals a gene signature prognostic of outcome. J Clin Oncol 28:1813-1820. doi: 10.1200/JCO.2009.22.8775
-
(2010)
J Clin Oncol
, vol.28
, pp. 1813-1820
-
-
Staaf, J.1
Ringner, M.2
Vallon-Christersson, J.3
Jonsson, G.4
Bendahl, P.O.5
Holm, K.6
Arason, A.7
Gunnarsson, H.8
Hegardt, C.9
Agnarsson, B.A.10
Luts, L.11
Grabau, D.12
Ferno, M.13
Malmstrom, P.O.14
Johannsson, O.T.15
Loman, N.16
Barkardottir, R.B.17
Borg, A.18
-
46
-
-
84862908745
-
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria
-
10.1093/jnci/djr490 22138096 10.1093/jnci/djr490 1:CAS:528: DC%2BC38XhsVWhsbw%3D
-
Perez EA, Dueck AC, McCullough AE, Reinholz MM, Tenner KS, Davidson NE, Gralow J, Harris LN, Kutteh LA, Hillman DW, Jenkins RB, Chen B (2012) Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst 104:159-162. doi: 10.1093/jnci/djr490
-
(2012)
J Natl Cancer Inst
, vol.104
, pp. 159-162
-
-
Perez, E.A.1
Dueck, A.C.2
McCullough, A.E.3
Reinholz, M.M.4
Tenner, K.S.5
Davidson, N.E.6
Gralow, J.7
Harris, L.N.8
Kutteh, L.A.9
Hillman, D.W.10
Jenkins, R.B.11
Chen, B.12
-
47
-
-
84860496688
-
Apocrine carcinoma as triple-negative breast cancer: Novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma
-
10.1093/jjco/hys034 22450930 10.1093/jjco/hys034
-
Tsutsumi Y (2012) Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma. Jpn J Clin Oncol 42:375-386. doi: 10.1093/jjco/hys034
-
(2012)
Jpn J Clin Oncol
, vol.42
, pp. 375-386
-
-
Tsutsumi, Y.1
-
48
-
-
79952654970
-
Molecular stratification of triple-negative breast cancers
-
10.1634/theoncologist.2010-S5-39 21138954 10.1634/theoncologist.2010-S5- 39 1:CAS:528:DC%2BC3MXltlWjsQ%3D%3D
-
Perou CM (2010) Molecular stratification of triple-negative breast cancers. Oncologist 15(Suppl 5):39-48. doi: 10.1634/theoncologist.2010-S5-39
-
(2010)
Oncologist
, vol.15
, Issue.SUPPL. 5
, pp. 39-48
-
-
Perou, C.M.1
|